A healthcare growth equity firm, known as Foresite Capital, announced that Molly He, PhD., has joined as a project partner. Previously, she was working at Illumina as a senior director for over 15 years. Foresite Company will be getting a professional who has experience in genomic research and pharmaceutical. The announcement was made by Foresite Managing director and Principal executive officer, Jim Tananbaum. According to Tananbaum, Dr. He is among the scientific researchers who are well respected and Foresite is lucky to have such an addition to the team as it continues to expand.
Dr. He studied at Nankain University and was awarded a Bachelor’s Degree in Biochemist and from the University of California, Los Angeles she got Ph.D. in protein biophysics. She has written and published over 20 documents and has more than 20 patent applications. She has also issued patents in the field personalizing medication and sequencing of next-generation. Doing this as well as the experience she had at Illumina working as a developer of protein reagent, makes her ideal for the Foresite Capital position. Together with the company, Dr. He will help in the development of next generation sequencing portfolio.
Jim Tananbaum graduate from Yale University with a B.S and B.S.E.E., from Harvard Medicine School with an M.D. from MIT with and M.S and Harvard Business School with an M.B.A. is the founder and the CEO of the Foresite Capital. He is known as an industry leader and has over 25 years of experience in the healthcare field. Not only does he practice it, but, he also invests in it. Some of the investments that he made were Tarse Therapeutics in 2012, Sequenta in 2013, and Allergen Research Corporation in 2015. He was also a partner at Sierra Ventures; here he worked to establish practices that will be used by the healthcare services investments. The returns that he got from his investment was what he used as Foresite capital.
Before starting the Foresite Capital, Tananbaum founded GelTex Pharmaceuticals. However, he sold the company for $1.6 billion. He also co-founded Theravance Biopharma, Inc. He founded Foresite Capital in 2011 with $1.1 Billion assets that were under management. The reason for setting up the firm was to collaborate with entrepreneurs with vision and focus on building value and improving patient care dramatically. More details can be found on his Crunchbase profile.
Follow him on Twitter
Click here: https://www.forbes.com/profile/jim-tananbaum/